The Pill and the Court: Inside the Legal Battle Over Mifepristone by Mail

On Friday, May 1, 2026, the Fifth Circuit Court of Appeals in New Orleans sided with Louisiana and reinstated an in-person dispensing requirement for mifepristone, the first drug in the two-pill medication abortion regimen [1]. By Monday morning, Justice Samuel Alito — who handles emergency matters from the Fifth Circuit — had issued an administrative stay, putting the appeals court ruling on hold and temporarily restoring mail access while the full Supreme Court considers the case [2]. The order gives Louisiana until May 8 to respond to emergency applications filed by drugmakers Danco Laboratories and GenBioPro, with the stay lasting until at least May 11 [2].

The whiplash — three days of legal uncertainty affecting a drug used in roughly two out of every three abortions nationwide — laid bare just how central mail-order mifepristone has become to reproductive healthcare in post-Dobbs America, and how fragile its legal foundation remains.

The Rise of Medication Abortion by Mail

Mifepristone was approved by the FDA in September 2000 for use in combination with misoprostol to terminate pregnancies up to 10 weeks' gestation [3]. For two decades, federal regulations required that the drug be dispensed in person at clinics or medical offices. That changed during the COVID-19 pandemic: in 2021, the FDA stopped enforcing the in-person requirement, and in 2023, the Biden administration finalized rules formally eliminating it [1].

The shift transformed how Americans access abortion. Medication abortion accounted for 63% of all U.S. abortions in 2023, up from 53% in 2020 and just 24% in 2011 [4]. Over 98% of medication abortions use the mifepristone-misoprostol combination [5].

Source: Guttmacher Institute

Data as of Mar 1, 2024CSV

Telehealth-prescribed, mail-delivered abortion grew even faster. According to the Society of Family Planning's #WeCount project, telehealth's share of all U.S. abortions rose from 5% in mid-2022 to 25% by the end of 2024 [6]. By 2025, an average of 12,330 abortions per month were being provided under state shield laws to patients in states with bans [6]. In total, 91,000 telehealth abortions were provided to patients in states with total bans in 2025 alone — including 9,350 in Louisiana [5].

Source: Society of Family Planning #WeCount

Data as of Mar 1, 2025CSV

What the Court Actually Did — and Didn't Do

The Supreme Court's Monday order is an administrative stay, not an injunction on the merits or even a ruling on the likelihood of success [2]. An administrative stay is the most preliminary form of Supreme Court intervention — a brief pause to preserve the status quo while the justices decide whether to grant more substantive relief. It does not reflect a judgment on whether the Fifth Circuit was right or wrong.

The procedural chain is important. Louisiana Attorney General Liz Murrill sued the FDA in October 2025, arguing that the agency's 2023 mail-dispensing rules effectively "cancel Louisiana's ban on medical abortions" [7]. A federal district judge in Louisiana expressed sympathy with the state's arguments but declined to issue a preliminary injunction, partly accepting a Trump administration argument that Louisiana's lawsuit suffered procedural defects [8]. The Trump administration's position was notable: while it stopped short of defending the FDA's regulatory approach on the merits, it argued the case should not go forward on procedural grounds [8].

Louisiana appealed. On May 1, a three-judge Fifth Circuit panel unanimously ruled that Louisiana was likely to prevail and granted its request to void the Biden-era mail rules [1]. Danco Laboratories, the manufacturer of brand-name Mifeprex, filed an emergency application with the Supreme Court the next day, warning of "immediate confusion and upheaval into highly time-sensitive medical decisions" [9]. GenBioPro, which makes the generic version, filed a separate application shortly after [10].

"While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences," Planned Parenthood said in a statement [2]. Murrill responded: "The administrative stay is temporary, and I am confident life and the law will win in the end" [2].

Standing: The Recurring Question

The standing question — whether the plaintiff has suffered a concrete injury that a court can redress — has haunted mifepristone litigation since the first major case.

In June 2024, the Supreme Court unanimously ruled in FDA v. Alliance for Hippocratic Medicine that the anti-abortion medical groups challenging the FDA's mifepristone approvals lacked standing [11]. None of the respondents prescribed or used mifepristone; they wanted the FDA to make the drug harder for other doctors to prescribe and other patients to obtain. The Court held that "a plaintiff's desire to make a drug less available for others does not establish standing" [11].

The Alliance for Hippocratic Medicine — an umbrella of five anti-abortion medical groups including the American Association of Pro-Life Obstetricians & Gynecologists and the Christian Medical & Dental Associations — was incorporated in Amarillo, Texas in 2022, despite none of its member organizations having members there [12]. The organization formally withdrew its claims in November 2024 [12].

Louisiana's lawsuit represents a different theory of standing. As a state with a total abortion ban, Louisiana argues it suffers a sovereign injury when federal regulations allow its residents to circumvent state law [7]. The Fifth Circuit found this argument plausible. Whether the Supreme Court agrees may determine the case's trajectory.

The Safety Record: 7.5 Million Prescriptions

Mifepristone's safety profile is among the most extensively studied of any pharmaceutical product. As of December 31, 2024, approximately 7.5 million people in the United States had taken mifepristone for medication abortion since its approval in 2000 [3]. The FDA's post-marketing adverse events report documented 36 deaths associated with the drug over that 24-year period — a rate of roughly 0.0005% [3].

The FDA report also documented 4,252 total adverse event cases and 1,056 hospitalizations (excluding deaths), of which 97 involved ectopic pregnancies [3]. Among the 36 deaths, 13 were associated with sepsis, including 9 cases that tested positive for Clostridium sordellii [3].

There is a critical limitation to these numbers that both sides of the debate sometimes obscure. The FDA's adverse event reporting system (FAERS) is a passive surveillance tool — healthcare providers and patients voluntarily report events they believe may be associated with a drug. As the FDA itself notes, these events "cannot with certainty be causally attributed to mifepristone because of information gaps about patient health status, clinical management of the patient, concurrent drug use, and other possible medical or surgical treatments and conditions" [3].

Challengers have pointed to these raw adverse event numbers as evidence of danger. The Guttmacher Institute and other reproductive health researchers counter that passive reporting databases are unreliable proxies for causation, and that the actual peer-reviewed evidence — including a study of 54,911 Medicaid-reimbursed abortions in California that found a major complication rate of 0.31% — demonstrates an exceptional safety record [13]. The American Medical Association, the American College of Obstetricians and Gynecologists, and the National Academies of Sciences, Engineering and Medicine have all affirmed mifepristone's safety [14].

A 2024 study published in Nature Medicine specifically examined telehealth medication abortion safety and found outcomes comparable to in-person provision [15].

Can Federal Courts Override the FDA?

The legal question at the heart of this case extends well beyond abortion. If the Fifth Circuit's reasoning holds, it would establish that federal courts can second-guess the FDA's scientific judgments about how a drug should be distributed — a power that food and drug legal scholars say courts have not historically exercised.

In amicus briefs filed during the earlier Alliance for Hippocratic Medicine case, legal scholars argued that lower courts had "replaced the FDA's scientific and medical expertise with the courts' own interpretations of the scientific evidence" and that such rulings "upend the drug regulatory scheme established by Congress and implemented by FDA" [16]. Former FDA commissioners and pharmaceutical industry executives warned of a potential upheaval to a drug approval process that has been in place for more than 60 years [16].

The strongest argument for court intervention rests on the Administrative Procedure Act: if the FDA's 2023 rule change was "arbitrary and capricious" — meaning it failed to adequately consider relevant factors or explain its reasoning — courts have authority to vacate it. The Fifth Circuit found the FDA's action wanting on these grounds, noting the agency "could not say when that review might be complete" regarding its ongoing safety reassessment [1].

Louisiana also raises a federalism argument: that the FDA cannot preempt state law by authorizing a distribution method that effectively nullifies state abortion bans. The state contends that every prescription mailed into Louisiana represents a violation of state sovereignty [7].

Defenders of FDA authority counter that Congress gave the agency exclusive power over drug safety and distribution through the Federal Food, Drug, and Cosmetic Act and the 2007 law authorizing Risk Evaluation and Mitigation Strategies (REMS) [16]. Under this view, state attempts to impose distribution restrictions beyond what the FDA requires are preempted by federal law — an argument with support in a Washington University Law Review article finding that "FDA leads, states must follow" on drug regulation [17].

13 States with Bans — But Federal Ruling Has National Reach

Thirteen states currently enforce total or near-total abortion bans [18]. These include Alabama, Arkansas, Idaho, Louisiana, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, West Virginia, and Wisconsin (with limited exceptions). Enforcement mechanisms vary: Arkansas, for instance, subjects physicians to up to 10 years in prison and $100,000 in fines [18]. Other states use civil liability, pharmacy-license revocation, or a combination.

The Fifth Circuit ruling, had it remained in effect, would have applied nationwide — not just in ban states. That is because it targeted the FDA regulation itself, not individual state enforcement. Even in states where abortion is legal, providers and pharmacies would have been required to return to in-person dispensing [5]. This nationwide scope is what made the ruling particularly disruptive: it affected the entire distribution infrastructure for mifepristone, not merely access in restrictive states.

How the Rest of the World Does It

The United States is an outlier among peer nations in the intensity of its mifepristone regulation. France approved mifepristone in 1988, and medication abortion is widely available through the country's healthcare system [19]. The United Kingdom allows nurses to administer the drugs as long as a physician prescribes them [20]. In Sweden, midwives can administer both mifepristone and misoprostol [20]. Canada approved mifepristone in 2015 and initially limited use to seven weeks' gestation, later extending the limit to nine weeks in 2017 [19].

Australia has been cited as a model for pharmacy-based mifepristone distribution. A 2015 study in Contraception described Australia's prescription-based pharmacy model as demonstrating the feasibility of expanding access beyond clinic settings [21]. Mifepristone is approved in nearly 100 countries worldwide [19].

These international experiences are relevant because challengers' core argument — that mifepristone requires in-person medical supervision for safety — must contend with decades of data from countries where the drug has been dispensed with fewer restrictions and comparable or better outcomes.

Shield Laws and Contingency Networks

Eight states have enacted shield laws that provide legal protection to providers who prescribe medication abortion via telehealth to patients in states with bans [22]. These laws have enabled a substantial distribution network: by the end of 2024, shield-law providers were facilitating an average of 12,330 abortions per month to patients in ban states [6].

If the Supreme Court ultimately rules against mail access on the merits, these networks would face significant disruption but would not disappear entirely. Several contingency mechanisms are already operational. Some providers have indicated they would pivot to misoprostol-only protocols, which are less effective than the mifepristone-misoprostol combination but are supported by medical organizations and are not subject to the same legal challenges [22]. International mail-order pharmacies, particularly those based in countries where mifepristone is available over the counter, represent another channel — though one that operates in legal gray areas.

The realistic timeline for a merits decision is uncertain. The Supreme Court could grant or deny certiorari after the emergency briefing is complete in mid-May 2026, but a full merits ruling would likely not come until the Court's next term, potentially in 2027. In the interim, the administrative stay and any subsequent injunctive relief will determine whether mail access continues.

What Comes Next

The immediate question is narrow: will the Supreme Court convert its administrative stay into a broader injunction pending appeal, or will it let the Fifth Circuit's ruling take effect? Louisiana must file its response by May 8, and the stay lasts through at least May 11 [2].

The broader question is whether the Court is prepared to rule on the merits of federal drug regulation in the context of abortion. The 2024 Alliance for Hippocratic Medicine decision sidestepped the merits entirely by resolving the case on standing. Louisiana's state-sovereignty theory of standing is more conventional, making it harder to dispose of on procedural grounds.

For the estimated one in four abortion patients who now receive care via telehealth [5], and for the drugmakers whose distribution models depend on mail access, the stakes are immediate and concrete. For the 13 states with abortion bans, the case tests whether federal regulation can create a pathway around state law. And for administrative law, the case asks whether courts can tell the FDA how to distribute an approved drug — a question with implications far beyond reproductive healthcare.